<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00901758</url>
  </required_header>
  <id_info>
    <org_study_id>INVERT-02</org_study_id>
    <secondary_id>CHREB #16682</secondary_id>
    <nct_id>NCT00901758</nct_id>
  </id_info>
  <brief_title>Intravenous (IV) Nitroglycerin for Versions in Multiparous Women</brief_title>
  <acronym>INVERT (02)</acronym>
  <official_title>Intravenous (IV) Nitroglycerin for Versions in Multiparous Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Breech presentations (where a baby presents with feet or bottom down) have an increased risk&#xD;
      of perinatal and neonatal complications, and are usually delivered by cesarean section. As an&#xD;
      alternative, so that the baby can be delivered vaginally, an attempt can be made to turn the&#xD;
      baby so that it is head down: this manoeuvre is called an external cephalic version (ECV).&#xD;
&#xD;
      Drugs that relax the uterus (tocolytic agents) are sometimes used to help improve ECV success&#xD;
      rates. Nitroglycerin is a tocolytic agent, but intravenous nitroglycerin has not been tested&#xD;
      as an agent to help ECV. There is some suggestion that nitroglycerin may be more helpful in&#xD;
      women who have not previously been pregnant (nulliparous women) than in women who have been&#xD;
      pregnant more than once (multiparous women), and so we have planned two trials.&#xD;
&#xD;
      This study is designed to answer the following questions for multiparous women:&#xD;
&#xD;
      Will administration of IV nitroglycerin for uterine relaxation improve ECV success rates?&#xD;
      Will an increase in ECV success result in a decreased cesarean section rate?&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success of ECV (if fetus turned from Breech to cephalic) at end of ECV procedure</measure>
    <time_frame>Recorded at the end of ECV attempt</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Success of ECV (ie fetus in cephalic presentation) recorded at time of delivery</measure>
    <time_frame>Recorded at time of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mode of delivery</measure>
    <time_frame>Recorded at time of birth</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maternal side effects and adverse events</measure>
    <time_frame>Recorded until date of birth (up to 3 weeks' duration).</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Breech Presentation</condition>
  <condition>Pregnancy Complication</condition>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo solution was normal saline. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment solution consisted of 100micrograms/mL of nitroglycerin. After an initial 1mL dose, further doses could be given in 1-3mL increments until uterine relaxation was achieved, or up to a recommended maximum of 10mL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV Nitroglycerin</intervention_name>
    <description>IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal saline</intervention_name>
    <description>IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  any non-cephalic presentation&#xD;
&#xD;
          -  singleton pregnancy&#xD;
&#xD;
          -  &gt;/= 37 weeks gestational age&#xD;
&#xD;
          -  normal amniotic fluid volume&#xD;
&#xD;
          -  reassuring fetal heart rate&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  labor&#xD;
&#xD;
          -  ruptured membranes&#xD;
&#xD;
          -  history of third trimester bleeding&#xD;
&#xD;
          -  any pre-existing uterine scar&#xD;
&#xD;
          -  pregnancy induced hypertension and gestational diabetes&#xD;
&#xD;
          -  oligohydramnios and polyhydramnios&#xD;
&#xD;
          -  intrauterine growth restriction or macrosomia&#xD;
&#xD;
          -  hypotension or any serious medical illness&#xD;
&#xD;
          -  inability to comprehend consent form&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce B Allan, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Calgary Health Region</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4J8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peter Lougheed Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rockyview Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Hilton J, Allan B, Swaby C, Wah R, Jarrell J, Wood S, Ross S, Tran Q. Intravenous nitroglycerin for external cephalic version: a randomized controlled trial. Obstet Gynecol. 2009 Sep;114(3):560-567. doi: 10.1097/AOG.0b013e3181b05a19. Erratum in: Obstet Gynecol. 2009 Nov;114(5):1148. Wah, Raouf [corrected to Wahba, Raouf].</citation>
    <PMID>19701035</PMID>
  </results_reference>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>May 13, 2009</study_first_submitted>
  <study_first_submitted_qc>May 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2009</study_first_posted>
  <last_update_submitted>August 27, 2013</last_update_submitted>
  <last_update_submitted_qc>August 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 28, 2013</last_update_posted>
  <responsible_party>
    <name_title>Dr B Allan</name_title>
    <organization>Department of Obstetrics and Gynecology, Rockyview General Hospital</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pregnancy Complications</mesh_term>
    <mesh_term>Breech Presentation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitroglycerin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

